How to Get Zetia (Ezetimibe) in New York

What Zetia (Ezetimibe) Is and Why New York Providers Prescribe It

Ezetimibe 10 mg once daily is an oral cholesterol-absorption inhibitor approved by the FDA for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia, either alone or combined with a statin. [1] It blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 50%, which lowers LDL-C by 18 to 20% as monotherapy. [2]

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 established that adding ezetimibe 10 mg to simvastatin 40 mg reduced major adverse cardiovascular events by 6.4% relative to simvastatin alone over a median 7-year follow-up (32.7% vs. 34.7%; hazard ratio 0.936 to 95% CI 0.89, 0.99; P<0.001). [3] That trial enrolled post-acute coronary syndrome patients with LDL-C between 50 to 125 mg/dL, and the absolute risk reduction was 2.0 percentage points. [3]

New York cardiologists and internists use ezetimibe most often in three scenarios: patients who cannot tolerate higher statin doses, patients on maximally tolerated statin therapy who still miss their LDL-C target, and patients with heterozygous familial hypercholesterolemia who need additive LDL lowering. The ACC/AHA 2022 guideline on non-statin therapies identifies ezetimibe as a first-line non-statin option for patients with atherosclerotic cardiovascular disease and LDL-C at or above 70 mg/dL on maximally tolerated statin therapy. [4]

Ezetimibe is generally well tolerated. The FDA label lists myalgia, upper respiratory infection, diarrhea, and arthralgia as the most common adverse events, each occurring in 2 to 4% of patients in clinical trials. [1] Serious hepatotoxicity is rare but the label recommends against use with cyclosporine or fibrates in certain populations. [1]

Telehealth Prescribing of Zetia in New York

New York State permits telehealth prescribing of non-controlled medications through a synchronous, real-time audio-video encounter. Ezetimibe is a non-scheduled drug, so no DEA exemption or in-person examination is legally required under New York Public Health Law §2999-cc. [5] The prescribing clinician must hold a current New York State license and must establish a valid patient-provider relationship during the telehealth visit.

Synchronous video is the standard. Audio-only visits may satisfy New York telehealth rules for established patients in limited circumstances, but most telehealth platforms require video for a new lipid management consultation to meet documentation standards. [5]

During a telehealth visit for ezetimibe, expect the clinician to review your most recent fasting lipid panel (dated within 90 days is typical), current statin dose if applicable, any prior statin intolerance history, a medication reconciliation for drug interactions, and your cardiovascular risk category using either the Pooled Cohort Equations or a documented clinical assessment. The entire visit usually runs 15 to 20 minutes.

Several telehealth platforms operating in New York offer lipid management consultations. When evaluating any platform, confirm the prescriber holds a New York State license, that the platform uses a synchronous video connection (not just asynchronous messaging), and that prescriptions are transmitted electronically to a New York-licensed pharmacy. The New York State Department of Health maintains a licensure look-up tool for verifying provider credentials. [6]

After the visit, the prescription is typically transmitted electronically to the pharmacy of your choice within minutes. Retail fulfillment at a New York pharmacy is usually same-day or next-day for generic ezetimibe 10 mg.

Required Labs Before Getting a Zetia Prescription in New York

A fasting lipid panel is the minimum required lab before any New York clinician will prescribe ezetimibe. This panel measures total cholesterol, LDL-C, HDL-C, non-HDL-C, and triglycerides after a 9 to 12 hour fast. [7] The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease recommends repeat lipid measurement 4 to 12 weeks after initiating any lipid-lowering drug to confirm efficacy and adherence. [8]

Additional labs that a thorough prescriber may request include:

• Liver function tests (ALT/AST). Ezetimibe alone rarely elevates transaminases, but concurrent statin therapy can, and baseline values help distinguish drug effect from pre-existing liver disease. The FDA label recommends monitoring when ezetimibe is combined with a statin. [1]
• Creatine kinase (CK). Relevant if the patient reports prior statin-associated myopathy. A baseline CK helps establish whether any future muscle symptoms are drug-related. [9]
• Thyroid-stimulating hormone (TSH). Hypothyroidism is a reversible secondary cause of hyperlipidemia; the 2022 ACC/AHA non-statin guideline recommends ruling it out before escalating lipid therapy. [4]
• Fasting glucose or HbA1c. Cardiovascular risk calculators incorporate diabetes status, and statin-associated new-onset diabetes is a documented adverse effect, so baseline glycemic data is clinically useful. [8]

New York LabCorp and Quest Diagnostics locations process fasting lipid panels with results available within 24 to 48 hours. Many telehealth platforms can order labs directly to a patient-selected draw site before the prescribing visit, so results are ready at the time of the consultation.

Who Can Prescribe Zetia in New York

Multiple license categories can legally prescribe ezetimibe in New York. MDs and DOs with a current New York State license have full prescribing authority for all non-controlled drugs. Nurse Practitioners (NPs) in New York gained full practice authority on January 1, 2023, under the Health Equity Access and Research Act, allowing independent prescribing without a physician collaboration agreement. [10] Physician Assistants (PAs) in New York retain prescriptive authority under the Physician Assistant Practice Act but must have a practice agreement with a supervising or collaborating physician. [11]

Clinical pharmacists in certain New York health systems have expanded collaborative drug therapy management agreements that permit them to adjust lipid medications within protocol, though they typically cannot initiate a new prescription for an unestablished patient without a physician order. [12]

For telehealth purposes, the most common prescribers you will encounter on New York-licensed platforms are MDs, DOs, and independently practicing NPs. All three can complete the initial consultation, order labs, prescribe ezetimibe 10 mg, and schedule a follow-up lipid recheck at 6 weeks.

Zetia Pharmacy Options in New York

Generic ezetimibe 10 mg tablets are manufactured by multiple companies including Amneal, Teva, Aurobindo, and Sun Pharma, and are widely stocked at New York retail pharmacies. [13] Without insurance, the GoodRx cash price at major New York City chains runs approximately $15, $28 for a 30-day supply as of mid-2025.

Retail chains. CVS, Walgreens, Rite Aid, Duane Reade, and Costco Pharmacy locations across New York State routinely carry generic ezetimibe. Costco's member pharmacy frequently offers the lowest cash price in the $15, $18 range.

Mail-order pharmacies. OptumRx, Express Scripts, and CVS Caremark mail-order divisions ship 90-day supplies to New York addresses. A 90-day supply of generic ezetimibe through mail-order typically costs $25, $45 with most commercial insurance plans.

Independent New York pharmacies. Over 1,200 independent pharmacies operate across New York State. Many participate in the National Community Pharmacists Association's discount program and can offer competitive cash pricing.

503A compounding pharmacies. Commercially manufactured ezetimibe 10 mg tablets are widely available, so 503A compounding of ezetimibe is uncommon. When it does occur (for example, a custom combination capsule pairing ezetimibe with a statin for a patient with documented swallowing difficulty), the pharmacy must hold a New York State Board of Pharmacy 503A registration, and the prescription must be issued for a specific named patient. [14] The New York State Board of Pharmacy publishes the list of registered compounding pharmacies at its official directory. [14]

Brand-name Zetia, manufactured by Organon (the successor to the original Merck/Schering-Plough joint venture), remains available but costs substantially more. Most insurance formularies place generic ezetimibe on Tier 1 or Tier 2, making the generic the default dispensed product in nearly all cases.

New York Medicaid and Insurance Coverage for Zetia

New York Medicaid covers ezetimibe for hyperlipidemia as an adjunct to dietary therapy, but requires prior authorization (PA) for most fee-for-service beneficiaries. [15] The PA criteria under New York Medicaid typically require documentation that the patient has an LDL-C above the guideline-recommended threshold for their cardiovascular risk category, that diet modification has been attempted, and that a statin is either being used concurrently or is contraindicated. [15]

For commercial insurance, the majority of large New York insurers (including Empire BlueCross BlueShield, UnitedHealthcare, Aetna, and Cigna) place generic ezetimibe on Tier 1 or Tier 2 with a $5, $30 copay. Step therapy requirements, which mandate trial of one or more statins before approving ezetimibe, are common on commercial plans but are partially constrained by New York's step therapy reform law (New York Insurance Law §3217-d), which requires insurers to allow a step therapy override when a clinician documents clinical contraindication or prior treatment failure. [16]

The ACC/AHA 2022 guideline states: "For patients with clinical ASCVD in whom LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy, ezetimibe is a reasonable first choice as add-on non-statin therapy." [4] That language is directly quoted in many New York commercial insurer PA forms as justification for approval without step therapy.

Merck's Zetia patient assistance program (the "Merck Patient Assistance Program") may cover brand Zetia at no cost for uninsured patients with household income at or below 600% of the federal poverty level. Details are available through the manufacturer's dedicated assistance line.

Prior Authorization Documentation for Zetia in New York

Prior authorization for ezetimibe in New York, whether through Medicaid or commercial insurance, follows a predictable documentation checklist. Preparing these records before the prescribing visit speeds up approval substantially.

Clinical documentation to gather:

1. Most recent fasting lipid panel with values and date
2. Current and prior statin prescriptions, including doses and dates
3. Any documentation of statin intolerance (e.g., myopathy notes, elevated CK values, or a provider note documenting intolerance)
4. Diagnosis codes (ICD-10 E78.5 for hyperlipidemia, unspecified; E78.01 for familial hypercholesterolemia; or Z82.49 for family history of cardiovascular disease)
5. Ten-year ASCVD risk score if the patient is in a primary prevention setting
6. Notes documenting dietary counseling attempts

New York's step therapy override law requires insurers to respond to an override request within 72 hours for non-urgent cases and within 24 hours for urgent cases. [16] If the insurer denies the PA, the prescribing clinician can file an expedited clinical appeal, and New York's external appeal process through the Department of Financial Services provides an independent review option if the internal appeal fails. [17]

Generic ezetimibe's low cash price ($15, $28 per month) means that many patients simply pay out of pocket while the PA process runs, then switch to insurance billing once approved.

Transferring an Existing Zetia Prescription to New York

If you move to New York with an active ezetimibe prescription from another state, federal law (21 U.S.C. §353) and New York Education Law §6810 permit the transfer of a non-controlled substance prescription between licensed pharmacies. [18] The receiving New York pharmacy contacts the out-of-state pharmacy directly to verify and transfer the remaining refills.

If refills are exhausted, the out-of-state prescription cannot be renewed by a New York pharmacy without a new prescribing encounter. A telehealth visit with a New York-licensed provider is the fastest path to a fresh prescription. During that visit, bring or upload your prior prescription records, most recent lipid panel results, and any documentation of prior statin use or intolerance to simplify the visit.

New York does not require a state-specific prescription form for non-controlled medications; electronic prescribing (e-prescribing) is actually mandated for most prescriptions in New York under the Internet System for Tracking Over-Prescribing (I-STOP) law. [19] Ezetimibe is a non-controlled drug and is fully covered under e-prescribing standards.

How Long Until You Receive Zetia in New York

The timeline from decision to first dose depends on the path chosen. A same-day telehealth visit with an available provider, combined with electronic transmission to a retail pharmacy, can result in same-day pickup at a New York City or suburban pharmacy. More rural New York locations may require next-day pickup if the pharmacy needs to order the medication.

Mail-order delivery to a New York address typically runs 3, 5 business days from prescription receipt. If prior authorization is required, insurance processing adds 24 to 72 hours in most cases under New York's PA response requirements. [16]

Below is a realistic best-case timeline for a new patient:

• Day 0. Schedule and complete telehealth visit; provider transmits e-prescription.
• Day 0, 1. Pharmacy verifies insurance or cash payment and fills prescription.
• Day 1. Patient picks up ezetimibe 10 mg at retail pharmacy.
• Week 6. Follow-up fasting lipid panel to confirm LDL-C response. The ACC/AHA 2019 guideline recommends this 4 to 12 week recheck. [8]

LDL-C reduction from ezetimibe typically reaches its full effect within 2 weeks of consistent daily dosing, as demonstrated in pharmacokinetic studies showing steady-state plasma concentrations achieved by day 14. [2]

Ezetimibe Dosing, Timing, and Drug Interactions

The approved dose is ezetimibe 10 mg once daily. It can be taken at any time of day, with or without food. [1] Unlike statins, ezetimibe does not require evening dosing for maximum efficacy because its mechanism targets intestinal absorption rather than hepatic cholesterol synthesis, which peaks at night.

Clinically relevant drug interactions in the New York patient population:

• Cyclosporine. Co-administration increases ezetimibe AUC by up to 12-fold and cyclosporine AUC by approximately 15%. Avoid combination or use only under specialist supervision. [1]
• Fibrates (fenofibrate, gemfibrozil). Gemfibrozil increases ezetimibe AUC by 1.7-fold; fenofibrate modestly increases it. The combination may increase the risk of cholelithiasis. [1]
• Cholestyramine and other bile acid sequestrants. Reduce ezetimibe AUC by approximately 55%. Administer ezetimibe at least 2 hours before or 4 hours after cholestyramine. [1]
• Warfarin. No pharmacokinetic interaction was detected in controlled studies, but any lipid-lowering regimen change in a patient on warfarin warrants an INR recheck within 1 to 2 weeks. [1]

Combination tablets containing ezetimibe plus simvastatin (brand Vytorin) or ezetimibe plus atorvastatin (brand Liptruzet) are FDA-approved and commercially available, and may simplify adherence for patients who are already on or starting a statin alongside ezetimibe. [20]

Monitoring After Starting Zetia in New York

After starting ezetimibe, the standard monitoring schedule follows ACC/AHA lipid guidelines. [8] A fasting lipid panel at 4 to 12 weeks confirms the LDL-C response; a 15 to 20% reduction from baseline is expected. [2] If response is inadequate, the clinician should assess adherence before escalating to a PCSK9 inhibitor such as evolocumab (Repatha) or alirocumab (Praluent). [4]

Liver enzyme monitoring is not required routinely for ezetimibe monotherapy under current FDA labeling, but ALT/AST should be checked at the same intervals as any co-prescribed statin, typically at 3 months and then annually. [1] Patients should report any new muscle pain, weakness, or brown urine promptly given the possibility of statin-associated myopathy when combination therapy is used. [9]

Annual fasting lipid panels thereafter are consistent with New York State Department of Health chronic disease management guidance for hyperlipidemia. [6] Dose adjustment of ezetimibe is not needed for mild-to-moderate renal impairment or mild hepatic impairment; it is not recommended in patients with moderate-to-severe hepatic impairment due to unknown effects on ezetimibe pharmacokinetics. [1]